Support Line: 0800 002 9002
General Enquiries: 01223 870008
Donate

News Archive

Sunitinib

Ilixadencel/Sunitinib Combo Therapy; Positive Results in mRCC

Ilixadencel/Sunitinib Combo Therapy; Positive Results in mRCC

Ilixadencel| Sunitinib
A combination therapy of ilixadencel plus sunitinib (Sutent) achieved complete tumor responses in patients with ...
2/1 schedual Sunitinib better than 4/2, says study

2/1 schedual Sunitinib better than 4/2, says study

Sunitinib
The Alternative 2/1 Schedule of Sunitinib is Superior to the Traditional 4/2 Schedule in Patients With Metastatic ...
Serious fatigue with Sorafenib & Sunitinib by RCC patients

Serious fatigue with Sorafenib & Sunitinib by RCC patients

Sunitinib
Sorafenib, and particularly sunitinib, worsened the severity of fatigue among patients with renal cell carcinoma ...
ASPEN Compares Sunitinib, Everolimus in Metastatic Non-Clear Cell Renal Cell Carcinoma

ASPEN Compares Sunitinib, Everolimus in Metastatic Non-Clear Cell Renal Cell Carcinoma

Everolimus| Sunitinib
Clinicians now have a better picture of what may be the optimal first-line therapy for patients with metastatic ...
Sunitinib and Sorafenib trial in locally advanced renal cell carcinoma

Sunitinib and Sorafenib trial in locally advanced renal cell carcinoma

Clinical Trials| Sorafenib| Sunitinib
Currently the targeted therapy drugs Sunitinib and Sorafenib are widely used in the UK for use in metastatic renal ...